Artificial intelligence and machine learning (AI/ML) has allowed for the identification of a number of compounds with potential use in treating COVID-19, but the results from those that have made it into clinical development have been rather mixed, according to a presentation at a recent conference on AI/ML in drug discovery, both for drugs repurposed as antivirals against SARS-CoV-2 and as anti-inflammatory agents.
The presentation, at the 30 October AI Cures Drug Discovery Conference sponsored by the Massachusetts Institute of Technology, looked at...